key: cord-0755752-p8n1qs63
authors: Catalán, Ignacio Pérez; Martí, Celia Roig; de la Sota, Daniela Palomo; Álvarez, Alejandro Cardenal; Gimeno, Maria José Esteve; Juana, Sergio Fabra; Rodríguez, Germán Herrero; Bajo, Elena Domínguez; Gaya, Nuria Tornador; Blasco, Jorge Usó; Rincón, Jose Manuel Ramos
title: Corticosteroids for COVID‐19 symptoms and quality of life at 1 year from admission
date: 2021-09-04
journal: J Med Virol
DOI: 10.1002/jmv.27296
sha: ef8a08c84bf0cc6556756121e7fcd9be29d8eecb
doc_id: 755752
cord_uid: p8n1qs63

The long‐term evolution of COVID‐19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID‐19 and explored the influence of treatment with systemic corticosteroids during the acute phase of the illness. This observational cohort study took place in a tertiary hospital in March and April 2021 and included people admitted due to infection with SARS‐CoV‐2 in March, April, or May 2020. We excluded patients who had died, were unreachable or had substantial cognitive impairment. A telephone survey was undertaken to assess the presence of symptoms related to COVID‐19 and to administer the SF‐36 quality of life questionnaire. Other variables collected were demographic and clinical data along with the treatment received and the evolution over time. We analyzed 76 patients, including 44 who did not receive corticosteroids and 32 who did. Most symptoms were less frequent in the group that received corticosteroids, with statistically significant differences for headache, dysphagia, chest pain, and depression. These patients also showed significantly better outcomes in the SF‐36 domains for “bodily pain” and “mental health.” Corticosteroids administered in the acute phase of COVID‐19 could attenuate the presence of long‐term symptoms and improve patients’ quality of life.

Recent contributions to the medical literature have described diverse clinical scenarios during follow-up, including the persistence of symptoms from the acute phase of illness, the onset of new symptoms in the postinfection period, exacerbation of symptoms that were present before the viral infection, and a wide range of post-COVID-19 sequelae. 8, 9 These situations should be detected to ensure treatment and improve patients' quality of life, which may be impaired following the acute episode. However, the best therapeutic approach and pharmacological management are currently unknown. 8 In this context, the health professionals participating in this study had the impression, from anecdotal observation, that patients who received corticosteroids during their admission had a better long-term evolution, with fewer symptoms related to the COVID-19 infection.

This study aims to test that hypothesis, analyzing the impact of corticosteroid treatment on the presence of symptoms and quality of life 1 year after initial admission with COVID-19.

This observational cohort study took place in a tertiary hospital in March and April 2021 and included adults (≥18 years) admitted to the infectious diseases ward due to COVID-19 in March, April, or May 2020. Infection with SARS-CoV-2 was confirmed by real-time polymerase chain reaction (RT-PCR) or serology. We excluded patients who had died, were unreachable or had substantial cognitive impairment.

A telephone survey was undertaken to assess the presence of symptoms related to COVID-19 (Annex 1). The questionnaire included items on the most frequently reported symptoms according to patient management guidelines in COVID-19. 8, 9 In their response to questions about whether they had specific symptoms, participants could answer yes or no, and if the symptom was present, specify whether it had appeared after the acute phase. There was also an open question about any other symptoms they had experienced, apart from those mentioned in the interview.

The survey on symptomology was followed by the SF-36 quality of life questionnaire. 10 

We used SPSS statistical software (v.23; IBM) for analyses. In the initial descriptive study, quantitative variables were expressed as the mean (95% confidence interval, CI) or median (interquartile range, IQR), depending on the normality of the distribution. Categorical variables were described as absolute and relative frequencies.

Statistical comparisons were undertaken, using the χ 2 test for categorical variables and the Student t-test or Mann-Whitney U test, as appropriate, to compare categorical with quantitative variables.

Our center's clinical research ethics committee approved the study. Patient confidentiality was preserved, and the performance of the study complied with the principles of the Declaration of Helsinki (2013) and good clinical practice rules.

A total of 124 patients were admitted for COVID-19 during the study period. We excluded 48 of these from the study (24 died, 13 presented significant cognitive impairment, and 11 were unreachable), for a final sample of 76 people, 32 of whom received corticosteroids and 44 of whom did not. Table 1 Regarding the complications experienced over the first year of follow-up, two patients-neither of whom received corticosteroidswere readmitted, one for stroke and the other for a urinary tract infection. The most frequently reported symptoms at 1 year of infection were forgetfulness (45.5% in patients that did not receive corticosteroid treatment vs. 43.8% in those who did), followed by asthenia (43.2% and 34.4% in the respective groups) and arthromyalgia (38.6% and 37.5%).

Patients who had received steroids presented significantly less headache, dysphagia, chest pain, and depression at 1 year. The rest of the symptoms also tended to appear less frequently in this group, with the exception of the loss of taste/smell, odynophagia, diarrhea, and alopecia. The steroids group also presented a lower number of symptoms (median 2, IQR 1-4) compared to the non-steroids group (median 3, IQR 1-6), although this difference was not significant (p = 0.25). These results are presented in full in Table 2 and Figure 1 .

Symptoms were seldom described as new in either group (Table 2) , and just eight people (10.5%) reported having no symptoms at the time of the interview.

Regarding the quality of life, Table 3 presents the median scores (IQR) for each domain of the SF-36 in the steroids and non-steroid group. The steroids group had better median scores than the nonsteroids group in four of the eight domains: bodily pain (100%, IQR 72.5%-100% vs. 75%, IQR 57%-100%; p = 0.017); general health perceptions (72.5%, IQR 55%-80%) versus 67.5%, IQR 40%-78.7%; p = 0.265); energy/vitality (80%, IQR 56.2%-85% vs. 62.5%, IQR 40%-85%; p = 0.120); and mental health (86%, IQR 69%-92% vs.

76%, IQR 54%-88%; p = 0.027). The median score was the same in both groups for the domains of physical role limitations, social functioning, and emotional role limitations (100%), although the IQRs were slightly better in the steroids group. In the remaining domain, physical functioning, median scores were comparable in people who received steroids (92.5%, IQR 75%-92.5%) and those who did not (95%, IQR 46.2%-100%; p = 0.81).

Our results suggest that patients who receive corticosteroids during their admission for COVID-19 are less likely to experience persistent symptoms and more likely to have a better quality of life at 1 year of admission.

The long-term persistence of COVID-19 symptoms is currently among the topics attracting the most scientific interest. However, our exhaustive literature search yielded few publications analyzing this aspect in patients who were admitted for this disease, and the studies that do exist are heterogeneous, have a limited follow-up, and do not examine the association with corticosteroids-the only treatment that has been proven to increase survival in the short term and whose use has been widely adopted globally. 7 Chopra et al. performed telephone interviews in 488 patients in Michigan (USA) 60 days after their admission due to COVID-19, and 32.6% reported persistent symptoms, including 18.9% who described new and sometimes worsening symptoms. 11 The most common were dyspnea, cough, and the persisting loss of smell and taste. In Wuhan 

We are grateful to the professionals in the Internal Medicine Service and the Infectious Diseases Unit at the Castellón General University

Hospital for their invaluable cooperation during the performance of the study, without which it would not have been possible. We also express our thanks to Meggan Harris for her assistance in editing.

The authors declare that they have no conflict of interest. 

Author elects to not share data. 

consumo y bienestar social

Johns Hopkins Coronavirus Resource Center

Real-time tracking of selfreported symptoms to predict potential COVID-19

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Personalized therapy approach for hospitalized patients with COVID-19

RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19

COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (UK)

Barcelona: Sociedad Catalana de Medicina Familiar i Comunitària (CAMFiC)

The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection

Sixty-day outcomes among patients hospitalized with COVID-19

Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a crosssectional evaluation

Gemelli against COVID-19 Post-Acute Care Study Group

Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study

Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission